

## LAP7 Rec'd PCT/PTO 25 MAY 2016 T

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Atty. Docket: FISHMAN=14A
In re Application of:	) Confirmation No.: 1479
Pnina FISHMAN et al	) Art Unit:
Appln. No.: 10/529,650	) Examiner:
I.A. Filed: 02/24/2005	) Washington, D.C.
For: TREATMENT OF HYPER- PROLIFERATIVE DISEASE	) May 25, 2006 )

## INFORMATION DISCLOSURE STATEMENT [IDS]

Customer Service Window, Mail Stop Amendment Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building, 401 Dulany Street Alexandria, Virginia 22314

## Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits.
- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

In re Appln. No. 10/529,650

3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:

Sheridan Neimark

Registration No. 20,520

SN:jec

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

G:\BN\C\cohn\FISHMAN14A\pto\2006-05-24 IDS.doc



Complete if Known Substitute for form 1449A/PTO 10/529,650 Application Number INFORMATION DISCLOSURE 02/24/2005 I.A. Filing Date Pnina FISHMAN et al STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1479 (use as many sheets as necessary) Confirmation No. Sheet FISHMAN=14A Attorney Docket Number of

_	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	r Cite No.1	Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
								AQ	WO 2004/038419

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	AR	Pnina FISHMAN et al; "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells"; Oncogene (2002), Vol. 21, pages 40604064.						
			-					
_			•					
_								
<del>u</del>	<u> </u>							
Exam Signa		Date Considered						

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.